@article{JTD5756,
author = {Jason A. Cook and Keyur B. Shah and Mohammed A. Quader and Richard H. Cooke and Vigneshwar Kasirajan and Kris K. Rao and Melissa C. Smallfield and Inna Tchoukina and Daniel G. Tang},
title = {The total artificial heart},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {12},
year = {2015},
keywords = {},
abstract = {The total artificial heart (TAH) is a form of mechanical circulatory support in which the patient’s native ventricles and valves are explanted and replaced by a pneumatically powered artificial heart. Currently, the TAH is approved for use in end-stage biventricular heart failure as a bridge to heart transplantation. However, with an increasing global burden of cardiovascular disease and congestive heart failure, the number of patients with end-stage heart failure awaiting heart transplantation now far exceeds the number of available hearts. As a result, the use of mechanical circulatory support, including the TAH and left ventricular assist device (LVAD), is growing exponentially. The LVAD is already widely used as destination therapy, and destination therapy for the TAH is under investigation. While most patients requiring mechanical circulatory support are effectively treated with LVADs, there is a subset of patients with concurrent right ventricular failure or major structural barriers to LVAD placement in whom TAH may be more appropriate. The history, indications, surgical implantation, post device management, outcomes, complications, and future direction of the TAH are discussed in this review.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/5756}
}